A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasisYu Chen, Gang Wang, Furen Zhang et al.|International Immunopharmacology|2022Cited by 12
Expert Consensus on Big Data Collection of Skin and Appendage Disease Phenotypes in ChineseShuang Zhao, Xiang Chen, Juan Tao et al.|Phenomics|2024Cited by 7